
Opthea Limited OPT
Annual report 2022
added 09-29-2022
Opthea Limited EV - Enterprise Value 2011-2026 | OPT
Annual EV - Enterprise Value Opthea Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.08 B | 2.13 B | 2.83 B | -8.58 M | 8.18 M | 5.68 M | 2.28 M | 2.5 M | 6.09 M | 3.98 M | 5.92 M | 42.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.83 B | -8.58 M | 592 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
1.16 B | $ 3.13 | 0.55 % | $ 651 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Exelixis
EXEL
|
11.9 B | $ 46.48 | 4.64 % | $ 12.6 B | ||
|
Fortress Biotech
FBIO
|
122 M | $ 2.5 | 1.63 % | $ 69.8 M | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | ||
|
Galapagos NV
GLPG
|
82.8 M | $ 28.79 | 1.41 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
27 B | $ 27.79 | 0.92 % | $ 17.1 B | ||
|
Genprex
GNPX
|
-3.98 M | $ 0.9 | 1.12 % | $ 839 K | ||
|
Grifols, S.A.
GRFS
|
11.8 B | $ 8.33 | 0.73 % | $ 6.83 B | ||
|
InflaRx N.V.
IFRX
|
-2.36 M | $ 2.51 | 27.51 % | $ 152 M | ||
|
Immuron Limited
IMRN
|
-20.4 M | $ 0.8 | 1.39 % | $ 6.7 M | ||
|
Ionis Pharmaceuticals
IONS
|
15.6 B | $ 76.27 | 1.36 % | $ 12.2 B | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 95.08 | -0.44 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Kamada Ltd.
KMDA
|
252 M | $ 8.28 | 0.85 % | $ 260 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
11.4 M | - | - | $ 231 M | ||
|
Kymera Therapeutics
KYMR
|
7.74 B | $ 85.67 | 3.58 % | $ 7.24 B | ||
|
Kazia Therapeutics Limited
KZIA
|
141 M | $ 13.28 | -1.26 % | $ 1.76 B | ||
|
INmune Bio
INMB
|
12.3 M | $ 1.54 | - | $ 38.1 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
2.26 B | $ 232.25 | -0.02 % | $ 4.25 B | ||
|
Liquidia Corporation
LQDA
|
3.04 B | $ 41.83 | 4.24 % | $ 3.6 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.89 | 2.42 % | $ 3.79 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 108.2 | 2.26 % | $ 5.43 B | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
MannKind Corporation
MNKD
|
1.76 B | $ 3.84 | 34.27 % | $ 1.17 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.51 | 0.29 % | $ 5.78 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 23.68 | 1.09 % | $ 3.01 B | ||
|
Nanobiotix S.A.
NBTX
|
99.5 M | $ 41.17 | 18.39 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M |